These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 23977840)
1. MP29-02: a breakthrough for the treatment of allergic rhinitis. Bernstein JA Expert Opin Pharmacother; 2013 Oct; 14(15):2101-13. PubMed ID: 23977840 [TBL] [Abstract][Full Text] [Related]
2. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. Bousquet J; Bachert C; Bernstein J; Canonica GW; Carr W; Dahl R; Demoly P; Devillier P; Hellings P; Fokkens W; Klimek L; Lieberman P; Meltzer E; Price D; Ryan D; Wahn U Expert Opin Pharmacother; 2015 Apr; 16(6):913-28. PubMed ID: 25747125 [TBL] [Abstract][Full Text] [Related]
3. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. Price D; Shah S; Bhatia S; Bachert C; Berger W; Bousquet J; Carr W; Hellings P; Munzel U; Scadding G; Lieberman P J Investig Allergol Clin Immunol; 2013; 23(7):495-503. PubMed ID: 24654314 [TBL] [Abstract][Full Text] [Related]
4. Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate. Derendorf H; Meltzer EO; Hermann R; Canonica GW Drugs Today (Barc); 2014 Jan; 50(1):15-31. PubMed ID: 24524103 [TBL] [Abstract][Full Text] [Related]
5. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. Berger WE; Shah S; Lieberman P; Hadley J; Price D; Munzel U; Bhatia S J Allergy Clin Immunol Pract; 2014; 2(2):179-85. PubMed ID: 24607046 [TBL] [Abstract][Full Text] [Related]
6. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Meltzer EO; LaForce C; Ratner P; Price D; Ginsberg D; Carr W Allergy Asthma Proc; 2012; 33(4):324-32. PubMed ID: 22856633 [TBL] [Abstract][Full Text] [Related]
7. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. Carr W; Bernstein J; Lieberman P; Meltzer E; Bachert C; Price D; Munzel U; Bousquet J J Allergy Clin Immunol; 2012 May; 129(5):1282-1289.e10. PubMed ID: 22418065 [TBL] [Abstract][Full Text] [Related]
8. Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. Klimek L; Bousquet J; Price D Expert Opin Drug Saf; 2016 Jan; 15(1):117-29. PubMed ID: 26581312 [TBL] [Abstract][Full Text] [Related]
9. A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis. Ridolo E; Montagni M; Melli V; Bonzano L; Incorvaia C; Canonica GW Ther Deliv; 2015; 6(6):653-9. PubMed ID: 25913181 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Klimek L; Bachert C; Mösges R; Munzel U; Price D; Virchow JC; Wahn U; Bousquet J Allergy Asthma Proc; 2015; 36(1):40-7. PubMed ID: 25562555 [TBL] [Abstract][Full Text] [Related]
11. Azelastine and fluticasone nasal spray: any advantage? Drug Ther Bull; 2014 Feb; 52(2):21-4. PubMed ID: 24504481 [TBL] [Abstract][Full Text] [Related]
13. MP29-02 for the treatment of seasonal allergic rhinitis: a review of clinical pharmacology, efficacy and safety. Berger WE Expert Rev Clin Immunol; 2013 Sep; 9(9):803-11. PubMed ID: 24070043 [TBL] [Abstract][Full Text] [Related]
14. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Derendorf H; Munzel U; Petzold U; Maus J; Mascher H; Hermann R; Bousquet J Br J Clin Pharmacol; 2012 Jul; 74(1):125-33. PubMed ID: 22356350 [TBL] [Abstract][Full Text] [Related]
16. Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Bernstein JA Curr Med Res Opin; 2007 Oct; 23(10):2441-52. PubMed ID: 17723160 [TBL] [Abstract][Full Text] [Related]
18. Comparison of azelastine versus triamcinolone nasal spray in allergic and nonallergic rhinitis. Kalpaklioglu AF; Kavut AB Am J Rhinol Allergy; 2010; 24(1):29-33. PubMed ID: 20109317 [TBL] [Abstract][Full Text] [Related]
19. Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis. Lieberman P; Kaliner MA; Wheeler WJ Curr Med Res Opin; 2005 Apr; 21(4):611-8. PubMed ID: 15899111 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ratner PH; Hampel F; Van Bavel J; Amar NJ; Daftary P; Wheeler W; Sacks H Ann Allergy Asthma Immunol; 2008 Jan; 100(1):74-81. PubMed ID: 18254486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]